Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen-Reference-Cited by-同舟云学术

Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen

Published:2021-03 Issue: Volume:Volume 14 Page:369-377
ISSN:1178-7066
Container-title:Pharmacogenomics and Personalized Medicine
language:en
Short-container-title:PGPM

Author:

Zhu Xiaoqin^ORCID,Zhu Jia^ORCID,Sun Feifei^ORCID,Zhen Zijun^ORCID,Zhou Dalei,Lu Suying,Huang Junting^ORCID,Que Yi^ORCID,Zhang Lian,Cai Ruiqing,Wang Juan,Zhang Yizhuo

Publisher

Informa UK Limited

Subject

Pharmacology,Molecular Medicine

Reference41 articles.

1. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

2. Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38), an Active Metabolite of Irinotecan (CPT-11), by Human UGT1A1 Variants, G71R, P229Q, and Y486D

3. Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study

4. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses

5. UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer;Technology in Cancer Research & Treatment;2024-01

2. Importance of pharmacologic considerations in the development of targeted anticancer agents for children;Current Opinion in Pediatrics;2022-12-23

3. Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma;Cancer Medicine;2022-03